Abramson Cancer Center Support Grant.
艾布拉姆森癌症中心支持拨款。
基本信息
- 批准号:10367691
- 负责人:
- 金额:$ 16.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-13 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:AreaAttentionAwardBedsBioethicsBioethics ConsultantsCOVID-19COVID-19 pandemicCancer BurdenCancer CenterCancer Center Support GrantCancer ModelClinicalClinical ResearchClinical TrialsCommunitiesCrowdingDecentralizationDecision MakingDevelopmentDiseaseEducational CurriculumEnrollmentEthical AnalysisEthicsFailureFosteringFutureGoalsIndividualInfrastructureInterviewJudgmentKnowledgeLeadLightLiteratureMalignant NeoplasmsMethodsMissionMonitorNational Cancer InstituteParentsPatientsPeer ReviewPersonsPhasePoliciesProcessProtocols documentationQualitative MethodsRecommendationResearchResearch ActivityResearch PersonnelResearch PriorityResource SharingResourcesSiteStructureSystemUnderrepresented PopulationsVariantWorkanticancer researchbaseeligible participantevidence basehealth economicsimplementation barriersimplementation scienceinformantnovelpandemic diseasepeerpressurerecruitsuccessuptake
项目摘要
Project Summary for “Prioritizing Clinical Trials at NCI Cancer Centers Before, During, and After the
COVID-19 Pandemic: A Descriptive and Ethical Analysis”
In contrast to other clinical areas, National Cancer Institute (NCI) Cancer Centers are required to prioritize trials
at the site level. However, Cancer Centers currently lack ethics guidance for how best to make prioritization
decisions. These decisions have traditionally been viewed as a matter of scientific peer review, rather than as
ethical judgments, and they have not been empirically studied. This is concerning given that allocation of
shared, limited institutional resources for research – from eligible participants and available research staff to
lab space and beds – has critical implications for who stands to benefit from research participation and
scientific progress. Without studying how Cancer Centers prioritize trials, it is not possible to identify areas of
variation, ethical challenges and concerns, or the strengths and weaknesses of different approaches. The
pandemic offers a compelling opportunity to examine Cancer Center trial prioritization, as COVID-19
demanded restrictions on in-person research activities and reduced cancer trial enrollments, even as many
new protocols were proposed, intensifying prioritization pressures. Overall, bioethics as a field has paid
insufficient attention to trial prioritization, especially by sites, and there is no widely-accepted ethics framework
to guide this task. There is, however, emerging discussion of trial prioritization developing in the literature –
and the pandemic has accelerated this progress, as sites struggled to prioritize an influx of COVID-19 trials. A
group of bioethicists, including the study lead on this proposal, developed a novel framework for consolidating
and prioritizing COVID-19 trials, with the potential for broader applicability to other disease areas. The
objective of the proposed research is to build on this framework and other resources to produce a new ethics
model for Cancer Center trial prioritization, using empirical bioethics and implementation science methods.
First, we will use in-depth interviews with Cancer Center Associate Directors of Clinical Research and other
knowledgeable informants to examine how Cancer Centers (selected on the basis of their size, type, and
region to maximize diversity of perspective) have prioritized trials before and during the pandemic. In particular,
interviews will probe ethical and implementation challenges, perceived successes and failures, desired
guidance, and lessons and plans for the future (Aim 1). Next, we will compare these descriptive findings
against the proposed ethics framework for prioritizing COVID-19 trials, identifying shortcomings, gaps, and
areas for revision and adaptation for the specific context of cancer (Aim 2). Finally, we will combine these
descriptive and normative analyses to develop a novel framework for ethical trial prioritization by Cancer
Centers, with a focus on feasibility of implementation (Aim 3). Together, these aims will build the bioethics
evidence base to inform Cancer Center trial prioritization policy, as well as whether and how NCI should guide
these decisions, while contributing to bioethics capacity building by facilitating ethical trial prioritization by
responsible decision-makers.
《美国国立卫生研究院癌症中心临床试验优先顺序》项目总结
新冠肺炎大流行:描述性和伦理学分析
与其他临床领域不同,国家癌症研究所(NCI)癌症中心被要求优先进行试验
在站点级别。然而,癌症中心目前缺乏关于如何最好地确定优先顺序的伦理指导
决定。这些决定传统上被视为科学同行审查的问题,而不是
道德判断,而且还没有经过实证研究。这是关于分配给
共享、有限的研究机构资源--从合格的参与者和可用的研究人员到
实验室空间和床位-对谁将从研究参与和
科学进步。如果不研究癌症中心如何确定试验的优先顺序,就不可能确定
差异、道德挑战和关切,或不同方法的优点和缺点。这个
大流行为检查癌症中心试验优先顺序提供了一个令人信服的机会,如新冠肺炎
要求限制面对面的研究活动,并减少癌症试验的登记人数,即使有
提出了新的协议,加大了确定优先顺序的压力。总体而言,生物伦理学作为一个领域已经取得了成效
对审判优先次序的重视不足,特别是按地点,而且没有得到广泛接受的道德框架
来指导这项任务。然而,在文献中出现了关于试验优先顺序的讨论-
疫情加速了这一进展,因为各网站都在努力确定涌入的新冠肺炎试验的优先顺序。一个
一组生物伦理学家,包括这项提议的研究带头人,开发了一个新的框架,以巩固
优先考虑新冠肺炎试验,有可能更广泛地适用于其他疾病领域。这个
拟议研究的目标是在这一框架和其他资源的基础上产生一种新的伦理
癌症中心试验优先排序模型,使用经验生命伦理学和实施科学方法。
首先,我们将深入采访癌症中心临床研究副主任和其他
知识渊博的线人,以检查癌症中心(根据其规模、类型和
(该区域为最大限度地扩大观点多样性)将大流行前和大流行期间的试验列为优先事项。特别是,
访谈将探讨道德和实施挑战、感知的成功和失败,以及期望的
指导、经验教训和未来计划(目标1)。接下来,我们将比较这些描述性发现
对照建议的道德框架确定新冠肺炎试验的优先顺序,找出缺点、差距和
为癌症的具体情况修订和适应的领域(目标2)。最后,我们将结合这些
描述性和规范性分析为癌症伦理试验优先顺序制定新的框架
中心,重点是实施的可行性(目标3)。这些目标将共同构建生命伦理学。
为癌症中心试验优先顺序政策提供信息的证据基础,以及NCI是否以及如何指导
这些决定有助于通过以下方式确定伦理试验的优先顺序,从而促进生物伦理能力建设
负责任的决策者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT H VONDERHEIDE其他文献
ROBERT H VONDERHEIDE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT H VONDERHEIDE', 18)}}的其他基金
Immunotherapy and Tumor Microenvironment in HIV/AIDS Cancer Patients
HIV/艾滋病癌症患者的免疫治疗和肿瘤微环境
- 批准号:
10249752 - 财政年份:2019
- 资助金额:
$ 16.25万 - 项目类别:
non-AIDS defining cancers (NADCs) among aging HIV+ individuals
老年艾滋病毒感染者中的非艾滋病定义癌症(NADC)
- 批准号:
10249743 - 财政年份:2019
- 资助金额:
$ 16.25万 - 项目类别:
Project 1: Clinical and immune impact of radiation and dual checkpoint blockade in patients
项目 1:辐射和双重检查点封锁对患者的临床和免疫影响
- 批准号:
10005190 - 财政年份:2017
- 资助金额:
$ 16.25万 - 项目类别:
相似国自然基金
多模态超声VisTran-Attention网络评估早期子宫颈癌保留生育功能手术可行性
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
Ultrasomics-Attention孪生网络早期精准评估肝内胆管癌免疫治疗的研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
Development of social attention indicators of emerging technologies and science policies with network analysis and text mining
利用网络分析和文本挖掘开发新兴技术和科学政策的社会关注指标
- 批准号:
24K16438 - 财政年份:2024
- 资助金额:
$ 16.25万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Improving Flexible Attention to Numerical and Spatial Magnitudes in Young Children
提高幼儿对数字和空间大小的灵活注意力
- 批准号:
2410889 - 财政年份:2024
- 资助金额:
$ 16.25万 - 项目类别:
Continuing Grant
The Information-Attention Tradeoff: Toward an Understanding of the Fundamentals of Online Attention
信息与注意力的权衡:了解在线注意力的基本原理
- 批准号:
2343858 - 财政年份:2024
- 资助金额:
$ 16.25万 - 项目类别:
Continuing Grant
The everyday learning opportunities of young children with attention and motor difficulties: From understanding constraints to reshaping intervention
注意力和运动困难幼儿的日常学习机会:从理解限制到重塑干预
- 批准号:
MR/X032922/1 - 财政年份:2024
- 资助金额:
$ 16.25万 - 项目类别:
Fellowship
Towards a cognitive process model of how attention and choice interact
建立注意力和选择如何相互作用的认知过程模型
- 批准号:
DP240102605 - 财政年份:2024
- 资助金额:
$ 16.25万 - 项目类别:
Discovery Projects
DDRIG in DRMS: Communicating risks in a sensational media environment-Using short video multimodal features to attract attention and reduce psychological reactance for persuasion
DRMS中的DDRIG:耸人听闻的媒体环境中沟通风险——利用短视频多模态特征吸引注意力,减少说服心理抵触
- 批准号:
2343506 - 财政年份:2024
- 资助金额:
$ 16.25万 - 项目类别:
Standard Grant
Assessing the Influence of Reading Fiction on Multiple Tests of Attention
评估阅读小说对注意力多重测试的影响
- 批准号:
24K16033 - 财政年份:2024
- 资助金额:
$ 16.25万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Attention機構に基づく異種集合マッチング方式の分析と新方式の提案
基于注意力机制的异构集合匹配方法分析及新方法的提出
- 批准号:
23K11218 - 财政年份:2023
- 资助金额:
$ 16.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Effects of instruction using focus of attention on performance of chest compressions.
使用注意力集中的教学对胸外按压表现的影响。
- 批准号:
23K09887 - 财政年份:2023
- 资助金额:
$ 16.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Assessing the Influence of SDGs Formulation on Managers' Perceptions and CSR Activities: An Attention-based View
评估可持续发展目标制定对管理者认知和企业社会责任活动的影响:基于注意力的观点
- 批准号:
23K01515 - 财政年份:2023
- 资助金额:
$ 16.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




